Preliminary data from Phase 2 trials of opaganib from Israel’s Redhill (reported here previously) on 40 hospitalized Covid-19 patients showed positive results. Patients receiving opaganib had significantly reduced dependence on ventilators and faster time to discharge. https://www.prnewswire.com/il/news-releases/redhill-s-phase-2-3-covid-19-candidate-opaganib-reduces-ards-related-blood-clotting-in-preclinical-model-813822864.html

Six moderate to severe Israeli coronavirus patients have shown clinical improvement with the new opaganib  treatment from Israel’s Redhill (see here previously). All required less supplemental oxygenation, had higher lymphocyte counts and less lung inflammation. https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15261

Israeli biotech Redhill has announced that another of its pipeline medicines RHB-107 (upamostat) is to be tested by the US National Institute of Allergy and Infectious Diseases (NIAID) against SARS-CoV2, the virus that causes COVID-19. (Redhill’s Opaganib is already saving … Continue reading →

Italy has approved Opaganib from Israel’s Redhill Biopharma to treat some 160 severe COVID-19 patients with severe respiratory problems at three hospitals in northern Italy. Phase2 tests on 131 US patients were positive and two critically ill Israeli patients are … Continue reading →

The US FDA has given approval for Israel’s Redhill Biopharma to market its RHB-105 (Talicia) treatment for the treatment of Helicobacter pylori (H. pylori). It follows successful Phase 3 trials, as reported (here) previously. H. pylori affects some 2 million … Continue reading →

Israeli biotech Redhill announced positive top-line results from its confirmatory Phase 3 study using its TALICIA treatment for H. pylori Infection. Of 455 trial participants, the antibiotic-resistant infection was eradicated completely in 85% of cases compared to 58% using an … Continue reading →

Israeli biotech Redhill announced positive results of the Phase 3 trial for RB-104 in treating Crohn’s disease which affects 1.5 million people worldwide. https://www.timesofisrael.com/redhills-drug-for-crohns-disease-shows-positive-results-study/

Israeli biotech Redhill has announced that the Phase 3 trial of its BEKINDA treatment for acute gastroenteritis and gastritis, on 321 patients in 21 US clinical sites, met its targets for efficacy and safety. There are some 179 million cases … Continue reading →